2023-508621-27-00已完成4 期
A Single Dose, Fed state, Crossover Replicate, Bioequivalence Study of Naproxen 500 mg/ Esomeprazole 20 mg modified-release tablets (Antibiotice S.A.) versus Vimovo® 500 mg/20 mg film coated tablets (Grunenthal GmbH)
Antibiotice S.A.1 个研究点 分布在 1 个国家目标入组 32 人开始时间: 2024年3月4日最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 32
- 试验地点
- 1
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 64 years（18-64 Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Clinical Trials Center
Scientific
Antibiotice S.A.
研究点 (1)
Loading locations...
相似试验
尚未招募
1 期
SINGLE DOSE CROSSOVER FULLY REPLICATE BIOEQUIVALENCE STUDY OF ATORVASTATIN CALCIUM TABLETS 80 MG IN HEALTHY, ADULT, HUMAN SUBJECTS UNDER FASTING CONDITIOBioequivalence study in healthy volunteers.Bioequivalence,AtorvastatinTCTR20170109003Bio-innova and Synchron Co., Ltd.40
尚未招募
不适用
A Single Dose Crossover Fully Replicate Bioequivalent Study of Atorvastatin Calcium Equivalent to 80-mg Tablets under Fasting Conditio1. Male/Female must be 18ᇋ years of age,body mass index (BMI) =18ᆭ kg/m2,inclusive.2. Must be in good health as determined by medical history,vital signs,and physical examination.3. Scree1. Known hypersensitivity to atorvastatin and its components.2. Past medical history of renal and hepatic insufficiency.3. Subject has a history of any illness that,in the opinion of the investigTCTR20161121002Ranbaxy (Thailand) Co., Ltd.40
招募中
4 期
A randomized, single dose, cross-over, replicated, open-label bioequivalence study comparing indacaterol/glycopyrronium (85/43mcg inhalation powder hard capsules) (PG341 [Celon Pharma] vs Ultibro Breezhaler [Novartis])2024-514725-38-00Celon Pharma S.A.40
进行中（未招募）
1 期
Single-Dose, Two Treatment, Four-Way Crossover Replicate Design to Assess the Bioequivalence of two Fentanyl Transdermal Delivery Systems MYLAN (25ug/h) and Durogesic Dtrans (25ug/h) in Healthy Volunteers under Naltrexone Block. - N/AEUCTR2005-002935-28-GBBertek Pharmaceuticals International Limited40
已完成
不适用
Pharmacodynamics end point study on Tetracosactide InjectioCTRI/2021/04/032482Sun Pharmaceutical Medicare Limited48